Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.
about
Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protectionThe renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin?Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actionsAcute treatment with relaxin protects the kidney against ischaemia/reperfusion injurySerelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.Cyclic nucleotide signalling in kidney fibrosis.Relaxin does not improve Angiotensin II-induced target-organ damage.Pregnancy complications and birth outcomes among women experiencing nausea only or nausea and vomiting during pregnancy in the Norwegian Mother and Child Cohort Study.Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockadeThe Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.Relaxin treatment reverses insulin resistance in mice fed a high-fat dietThe emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatmentSerelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes.Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein.Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.Serelaxin a novel treatment for acute heart failure.Endothelial dysfunction and vascular disease - a 30th anniversary update.Anti-fibrotic actions of relaxin.Does serelaxin treatment alter passive mechanical wall properties in small resistance arteries?Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.Structural commonality of C1q TNF-related proteins and their potential to activate relaxin/insulin-like family peptide receptor 1 signalling pathways in cancer cells.Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia.Effects of serelaxin on renal microcirculation in rats under control and high-angiotensin environments.Relaxin-mediated renal vasodilation in the rat is associated with falls in glomerular blood pressure.Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.The actions of relaxin on the human cardiovascular system.Protective effects of long-term administration of Ziziphus jujuba fruit extract on cardiovascular responses in L-NAME hypertensive rats.Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.
P2860
Q26740185-38273685-B85E-47BC-B436-5EA3C15A69EEQ27003301-05008F54-021A-41CB-ABEC-EDCC7FBE0922Q33970136-AA0D59CC-412D-47E1-A7F2-1D7ED39CAAC5Q33982388-E8841068-3B7A-4325-BFF7-2C19DDE5E0BBQ34726868-16E61396-9A0D-436A-9CC7-0263CB6D131AQ35138860-B162F441-27E6-41DC-BE76-52A69D7DF6D8Q35141812-CCFC1556-9621-4C2A-A061-165A37E0C5A2Q35671229-9C50EE45-6FD4-4FF1-A001-B584B4EFDDD0Q36141224-F982E675-A95A-4911-9908-E8098F4515F8Q36749450-EF09053A-23EF-4F74-9EBD-195B9A7DE9ADQ37110579-F3BF5522-900C-4E62-B9E0-51A504ED0CBDQ37147122-8BA53E0A-73DF-4955-B4BC-4A9D242E2F55Q37405208-85745B1C-DA2E-4633-8771-691246ABA952Q37571303-FBB39D81-FE5F-487E-ACB9-D91A70D6BC32Q38080804-538A39EE-6776-489D-8779-0FE3285C93DBQ38220684-E86D3D14-5408-4FF7-B3F4-D20C03DB16F6Q38383238-A02B060D-CF43-4893-A4F0-C8C58AA48DEFQ38570717-5DE6E60B-7EB9-4337-9F32-99C8B83793ECQ38680112-FB9841DE-A527-438A-8579-80EC13A8123EQ38850557-C367AAC8-7F5D-46FE-8CCA-BD71158FC57CQ38960703-40AED03D-3E5F-4424-AF4F-8BEBCCFDA0B0Q38978007-4506784C-F4DE-4A8A-8FAC-75E5E6E86E15Q40604650-94532378-353F-41C0-90DC-CFAB6C36697FQ45350029-B61C208C-CBBA-4725-B8AF-280733D93643Q47619900-41F7A440-AC87-4624-8570-8C25A608ADD3Q50091258-2A8EC29A-5C31-418C-A15E-F102FBFD0CD7Q52674866-5ECD4C72-6B22-4E55-9DD2-4B12513FD62FQ52851745-F06BCA43-7DBB-4880-BFCD-E42F0B8F4E4DQ54944425-654ECD82-4268-482D-8C4A-FF17807B9EA0Q55209012-78D3CAC9-1D03-4DF8-A55C-FD3323FE02B8
P2860
Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Relaxin ameliorates hypertensi ...... ethyl ester hypertensive rats.
@ast
Relaxin ameliorates hypertensi ...... ethyl ester hypertensive rats.
@en
type
label
Relaxin ameliorates hypertensi ...... ethyl ester hypertensive rats.
@ast
Relaxin ameliorates hypertensi ...... ethyl ester hypertensive rats.
@en
prefLabel
Relaxin ameliorates hypertensi ...... ethyl ester hypertensive rats.
@ast
Relaxin ameliorates hypertensi ...... ethyl ester hypertensive rats.
@en
P2860
P1433
P1476
Relaxin ameliorates hypertensi ...... ethyl ester hypertensive rats.
@en
P2093
Chris Baylis
Miklos Molnar
P2860
P304
P356
10.1161/HYPERTENSIONAHA.110.164392
P407
P577
2011-06-13T00:00:00Z